Primer on Diabetes Management

Symposium on Diabetes and Cancer 2017: Novel Links and Treatments

S. Inzucchi

ACC 2022: An Embarrassment of Riches - Updated Guideline Recommendat…

ACC 2022 Conference Coverage

P. Heidenreich

ACC 2023: SGLT2i Use - Dos and Don'ts

ACC 2023 Conference Coverage

A. Armbruster

Which Diuretic(s) Are Best in HF? Update Based on Recent Clinical Tr…

MUSC Cardiology

R. Mentz

Coronary CTA for Assessing CAD - Are We There Yet?

Matthew Budoff

Diabetes Treatment Guidelines Finally Have Entered the 21st Century …

ASPC 2019 Congress on CVD Prevention

R. DeFronzo

Heart Failure With Preserved Ejection Fraction (HFpEF)

Amaninderapa Ghotra

Renal, Metabolic and Cardiovascular Considerations of SGLT2 Inhibiti…

Cardiology Fiesta 2017

R. DeFronzo

SGLT2 Inhibitors, GLP1 Receptor Agonists, and Renal Outcomes

Cardiometabolic Health Congress (CMHC)

L. Sloan

SGLT2 Inhibitors: For Heart Failure, Diabetes, and Renal Disease

Rita Jermyn

Cholesterol Treatment Decisions: Recent Updates to Guidelines and St…

Gary Martin

AHA 2022: Torsemide Comparison With Furosemide for Management of Hea…

AHA 2022 Conference Coverage

R. Mentz

2021 ADA Highlights: Heart Failure With Reduced Ejection Fraction - …

Michelle Kittleson

Hypertension 2025: New Guidelines and Resistant Hypertension

University of Louisville

K. Ferdinand

Management of Heart Failure

Obafemi Awolowo University

O. A. Akinyele

Anti-Obesity Medications

Michigan Medicine

D. H. Griauzde

HFpEF or Amyloidosis? The Right Therapies for Right Patients

Scripps Health

M. Kittleson

The Best of AHA23 for the Primary Care Doctor

Cecilia Bahit

Cardiac Amyloidosis: A New Era of Diagnostics and Therapeutics

UCLA Health

D. Vucicevic

An Efficient Approach to Addressing Syncope in the Office

Dr. Vu Kiet Tran

V. Tran